INDUSTRY / PUBLIC SOURCE RECORD
Radiopharma
- The page promotes Norway for investment and sustainable radiopharmaceutical production, citing decades of research and innovation, companies across development/manufacturing/transport/distribution, a complete value chain, proton-therapy and research centres, infrastructure for clinical trials and a role in theranostics. It highlights large-scale production and logistics of therapeutic radiopharmaceuticals, future local access to medical isotopes, central Nordic location, low electricity prices and renewable hydropower for energy-intensive production.
- Company links shown on the page: Actithera; Agilera Pharma AS; Artbio AS; Bayer Norway; Blue Wave Therapeutics; Cody; Curida Diatec; GE Healthcare AS; Kongsberg Beam Technology; Node Pharma AS; Nuclithera AS; Oncoinvent ASA; Norsk Medisinsk Syklotronsenter AS; Thor Medical; and Thorium Norway.
- Linked articles cover Norway’s role in alpha therapy/radiopharmaceuticals, theranostics as precision cancer treatment, Norway as a clinical-trial destination, and nuclear-medicine imaging and diagnostics. The investment call to action offers information, networks and site-selection assistance, linking to Invest in Norway’s health and life-science team.
- Public contacts: Rasmus Malmborg, Investment Manager, Health and life science, Oslo; rasmus.malmborg@innovasjonnorge.no; +47 951 21 480. Jannik Grodt Schmidt, Investment Manager, Health and life science, New York, USA; jannik.grodt.schmidt@innovationnorway.no; +1 917 972 6387; linkedin.com/in/jannikschmidt82/.
- No event listings, fees or participation prices are displayed on this page.